Skip to content

Inflammation as a Predictor in Cardioversion of Atrial Fibrillation

Inflammation as a Predictor in Cardioversion of Atrial Fibrillation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00590525
Enrollment
45
Registered
2008-01-10
Start date
2004-10-31
Completion date
2009-06-30
Last updated
2009-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

hsCRP

Brief summary

The laboratory test, C-Reactive Protein (CRP), has become well established as a marker of inflammation. Recently a high CRP level (indicating an increase in inflammation) was identified as a risk factor for atrial fibrillation. We are conducting this study with patients such as yourself with atrial fibrillation who are planning to undergo cardioversion to determine what sort of relationship exists between CRP levels and atrial fibrillation. We will then look at success rates of converting atrial fibrillation to normal sinus rhythm, compared to patients' CRP levels.

Interventions

PROCEDURECardioversion

Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark

Sponsors

Creighton University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Atrial fibrillation patients referred for DC cardioversion * On stable medical therapy

Exclusion criteria

* Known chronic inflammatory states such as infections, rheumatoid arthritis or known vasculitides. * Patients having undergone recent surgery or who are on steroid therapy for any reason will be excluded.

Design outcomes

Primary

MeasureTime frame
We hypothesize that a higher hsCRP is associated with higher failure rates in patients undergoing cardioversion for atrial fibrillation1 month

Secondary

MeasureTime frame
secondary endpoint will be if a new inflammatory disease state is diagnosed at the one-month mark.1 month

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026